352437-09-3

Basic information

• Product Name: 4-(4-BROMO-PHENYL)-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER
• Synonyms: 4-(4-BROMO-PHENYL)-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;1-Boc-4-(4-Bromophenyl)piperazine;4-(4-Boc-Piperazino)-1-bromobenzene;tert-Butyl 4-(4-bromophenyl)piperazine-1-carboxylate;t-Butyl 4-(4-Bromophenyl)piperazine-1-carboxylate;1-Piperazinecarboxylic acid, 4-(4-broMophenyl)-, 1,1-diMethylethyl ester;1-tert-Butoxycarbonyl-4-(4-broMophenyl)piperazine;tert-Butyl 4-(4-bromophenyl)piperazine-1-carboxylate, 1-(4-Bromophenyl)-4-(tert-butoxycarbonyl)piperazine
• CAS NO: 352437-09-3
• Molecular Formula: C₁₅H₂₁BrN₂O₂
• Molecular Weight: 341.24
• Product Categories: Heterocycles;Aryl;Organohalides
• Mol File: 352437-09-3.mol
• Article Data: 28

Chemical Properties

• Melting Point: 146.3-147.5 °C
• Boiling Point: 424.7°C at 760 mmHg
• Flash Point: 210.6°C
• Appearance: /
• Density: 1.332g/cm³
• Vapor Pressure: 2.03E-07mmHg at 25°C
• Refractive Index: 1.557
• Storage Temp.: Room temperature.
• PKA: 2.83±0.10(Predicted)
• CAS DataBase Reference: 4-(4-BROMO-PHENYL)-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-BROMO-PHENYL)-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(352437-09-3)
• EPA Substance Registry System: 4-(4-BROMO-PHENYL)-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(352437-09-3)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 352437-09-3(Hazardous Substances Data)

Usage

Uses

1-BOC-4-(4-Bromophenyl)piperazine is a reagent used in the synthesis of dual Bcl-2/Bcl-xL inhibitors.

InChI:InChI=1/C15H21BrN2O2/c1-15(2,3)20-14(19)18-10-8-17(9-11-18)13-6-4-12(16)5-7-13/h4-7H,8-11H2,1-3H3

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 66698-28-0 1-(4-bromophenyl)piperazine 
• 77278-40-1 tert-butyl 4-(benzoyloxy)piperazine-1-carboxylate 
• 183677-71-6 2-(4-bromophenyl)-5,5-dimethyl-1,3,2-dioxaborinane 
• 5467-74-3 4-Bromophenylboronic acid 
• 821-48-7 bis-(2-chloroethyl)amine hydrochloride 
• 106-40-1 4-bromo-aniline 
• 589-87-7 1,4-bromoiodobenzene 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 106-37-6 1.4-dibromobenzene 

Downstream Products

• 151978-66-4 tert-butyl 4-(4-iodophenyl)tetrahydro-1(2H)-pyrazinecarboxylate 
• 457613-78-4 4-(4-(tert-butoxycarbonyl)piperazin-1-yl)phenylboronic acid 
• 1056624-11-3 2-(4-piperazin-1-yl-phenyl)-pyrimidine hydrochloride 
• 942189-35-7 4-(4-pyrimidin-2-yl-phenyl)-piperazine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

MONOACYLGLYCEROL LIPASE INHIBITORS

Provided are compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof: Also provided are compositions comprising compounds of formula (I). The compounds and compositions are also provided for use as medicaments, for example as medicaments useful in the treatment of a condition modulated by monoacylglycerol lipase (MAGL). Also provided are the use of compounds and compositions for the inhibition of monoacylglycerol lipase (MAGL).

POLYCYCLIC COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES

The present disclosure relates to bifunctional compounds, ULM— L—PTM, which find utility as modulators of Rapidly Accelerated Fibrosarcoma (RAF, such as c-RAF, A- RAF and/or B-RAF; the target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein RAF, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein, or the constitutive activation of the target protein, are treated or prevented with compounds and compositions of the present disclosure.

RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

Provided herein are a RET inhibitor, a pharmaceutical composition thereof and uses thereof. In particular, provided is a compound having Formula (I) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof. Provided is a pharmaceutical composition comprising the compound, and uses of the compound and pharmaceutical composition thereof for the preparation of a medicament, in particular for treatment and prevention of RET-related diseases and conditions, including cancer, irritable bowel syndrome, and/or pain associated with irritable bowel syndrome.